Devyser Diagnostics Chairman Acquires 2.6% More Stock

Those following along with Devyser Diagnostics AB (publ) (STO:DVYSR) will no doubt be intrigued by the recent purchase of shares by Mia Arnhult, Chairman of the company, who spent a stonking kr11m on stock at an average price of kr107. While that only increased their holding size by 2.6%, it is still a big swing by our standards.

Check out our latest analysis for Devyser Diagnostics

The Last 12 Months Of Insider Transactions At Devyser Diagnostics

In fact, the recent purchase by Mia Arnhult was the biggest purchase of Devyser Diagnostics shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of kr112 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Devyser Diagnostics share holders is that insiders were buying at near the current price.

Happily, we note that in the last year insiders paid kr19m for 203.65k shares. But they sold 75.00k shares for kr7.2m. In the last twelve months there was more buying than selling by Devyser Diagnostics insiders. They paid about kr92.45 on average. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does Devyser Diagnostics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Devyser Diagnostics insiders own 43% of the company, worth about kr785m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

What Might The Insider Transactions At Devyser Diagnostics Tell Us?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Devyser Diagnostics. Nice! If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

Of course Devyser Diagnostics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com